Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months. (Q43000409)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

title

Combined treatment of relapse of chronic hepatitis C with high-dose alpha2b interferon plus ribavirin for 6 or 12 months (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference

1 reference

1 reference

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Vito Di Marco

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

Donatella Ferraro

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

P Almasio

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

A Vaccaro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

P Parisi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

M G Cataldo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

R Di Stefano

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 September 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

456-462

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

Clinical outcomes after transfusion-associated hepatitis C.

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

The effect of interferon on the liver in chronic hepatitis C: a quantitative evaluation of histology by meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Long-term course of interferon-treated chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Efficacy of a second cycle of interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Viral and host factors in determining response of relapsers with chronic hepatitis C to retreatment with interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Re-treatment with interferon alfa of patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Re-treatment of chronic hepatitis C with consensus interferon .

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Long-term interferon alfa-2b retreatment of relapsing patients with chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: a multicenter, controlled, randomized trial. Le Groupe D'étude et De Traitement du Virus De L'hépatite C (Get.Vhc)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Chronic hepatitis C: interferon retreatment of relapsers. A meta-analysis of individual patient data. European Concerted Action on Viral Hepatitis (EUROHEP).

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Ribavirin and interferon alfa-2b in chronic hepatitis C: assessment of possible pharmacokinetic and pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon alfa on viral turnover

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Effects of ribavirin on intrahepatic and extrahepatic expression of hepatitis C virus in interferon nonresponsive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Ribavirin polarizes human T cell responses towards a Type 1 cytokine profile.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2980282-2

7 January 2021

10.1016/S0168-8278(00)80282-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11020002%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference